The USRDS: what you need to know about what it can and can't tell us about ESRD.
暂无分享,去创建一个
[1] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.
[2] Winfried März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .
[3] R. Foley,et al. Long interdialytic interval and mortality among patients receiving hemodialysis. , 2011, The New England journal of medicine.
[4] J. Coresh,et al. Prevalence of chronic kidney disease in the United States. , 2007, JAMA.
[5] W. Suki,et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.
[6] R. Foley,et al. Atherosclerotic Renovascular Disease in Older US Patients Starting Dialysis, 1996 to 2001 , 2006, Circulation.
[7] G. Moneta. Atherosclerotic Renovascular Disease in Older US Patients Starting Dialysis, 1996 to 2001 , 2008 .
[8] M. Rocco,et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] E. Rackow. Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.
[10] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.